Xeris Biopharma Holdings reported second-quarter 2026 results with total revenue of $92.1 million, a 29% increase year-over-year, driven by an 81% surge in Recorlev net product revenue to approximately $57 million. Net product revenue grew 34% to $91 million, while Gvoke and Keveyis revenues remained relatively stable. The company reported a net loss of $31.1 million for the quarter, primarily due to a one-time non-cash charge of roughly $31 million related to fair value adjustments on its 2028 Convertible Notes exchange agreements. Adjusted EBITDA improved to $19.3 million from $12.5 million in the prior year period. Management tightened full-year 2026 total revenue guidance to a range of $385 million to $390 million, reflecting confidence in commercial momentum and strategic investments. Xeris Biopharma operates in the biopharmaceutical industry, developing and commercializing innovative therapies for endocrine and rare diseases.

Xeris Biopharma Holdings, Inc. completed privately negotiated exchange transactions for its 8.00% Convertible Senior Notes due 2028, exchanging approximately $28.5 million in aggregate principal amount of the 2828 Notes for approximately 5.0 million shares of common stock and $23 million in cash. Additionally, a holder of $10.5 million in principal amount of the 2828 Notes converted their notes into approximately 3.6 million shares of common stock. Following these transactions, no 2028 Notes remain outstanding. Xeris Biopharma Holdings, Inc. is a biopharma company that develops and commercializes biopharmaceutical products.

Xeris Biopharma Holdings, Inc. expanded its Board of Directors to eight members and appointed Nerissa Kreher, M.D., as a Class III director, effective July 1, 2026. Dr. Kreher's initial equity award has a combined aggregate grant date fair value of approximately $450,000. Additionally, the Board appointed John Shannon, the Company's CEO, to serve as Chairperson of the Board, effective July 1, 2026, and designated Marla S. Persky as Lead Independent Director. Xeris Biopharma Holdings, Inc. is a biopharmaceutical company that develops and commercializes biopharmaceutical products.

On June 10, 2026, Xeris Biopharma Holdings, Inc. entered into exchange agreements with holders of its 8.00% Convertible Senior Notes due 2028. Noteholders agreed to exchange approximately $23 million in aggregate principal—representing about 69% of the outstanding 2028 Notes—for a combination of cash and common stock. The cash portion equals the principal amount of the exchanged notes, funded by on-hand liquidity, while the share portion will be based on the 21-day volume-weighted average price starting June 11, 2026. The transaction is expected to close around July 15, 2026, leaving $10.5 million of the 2028 Notes outstanding. The company is a biopharmaceutical company that develops and commercializes injectable therapies.